|1.||Cross, Nicholas C P: 15 articles (12/2015 - 08/2002)|
|2.||Tefferi, Ayalew: 11 articles (03/2014 - 11/2003)|
|3.||Gotlib, Jason: 8 articles (12/2015 - 01/2006)|
|4.||Pilotti, Silvana: 8 articles (11/2015 - 11/2004)|
|5.||Gronchi, Alessandro: 7 articles (11/2015 - 11/2004)|
|6.||Reiter, Andreas: 6 articles (12/2015 - 02/2007)|
|7.||Haferlach, Claudia: 6 articles (12/2015 - 02/2007)|
|8.||Tamborini, Elena: 6 articles (11/2015 - 11/2004)|
|9.||Ostman, Arne: 6 articles (07/2009 - 10/2002)|
|10.||Metzgeroth, Georgia: 5 articles (12/2015 - 02/2007)|
01/01/2014 - "The levels of urinary PDGFRB were significantly correlated with the risk of 3-year recurrence of NMIBC, and these levels improved the accuracy of a NMIBC recurrence risk prediction model that included age, tumor size, and tumor number (area under the curve, 0.862; 95% CI, 0.809 to 0.914) compared to PDGFR alone. "
06/01/2014 - "However, patients with PDGFRB CNG >40% of tumor cells had improved relapse-free survival (HR 0.25 [95% CI 0.09-0.72], P=.0096) and improved overall survival (HR 0.32 [95% CI 0.11-0.89], P=.029). "
07/14/2010 - "In conclusion, the present study reveals a novel approach to target key cell types in tumors through PDGFR-beta, which can be applied to enhance the therapeutic efficacy of anticancer drugs."
11/01/2012 - "Therapeutic inhibition of PDGFRB markedly prolonged survival of NPM-ALK transgenic mice and increased the efficacy of an ALK-specific inhibitor in transplanted NPM-ALK tumors. "
09/01/2008 - "Recent studies have suggested that PDGFR-beta inhibition reduces tumor IFP, and thus increases the uptake of concomitantly administered drugs. "
06/01/2004 - "Blockade of PDGFR-beta may be a clinical approach to inhibit intimal hyperplasia in humans, but this study raises concerns about the long-term efficacy of this treatment."
09/12/2000 - "In the present study, we wanted to assess whether a single local endovascular delivery of antisense PDGFR-beta in injured rat carotid arteries would be sufficient to prevent intimal hyperplasia and how it might contribute to the vascular healing process. "
09/12/2000 - "Bolus endovascular PDGFR-beta antisense treatment suppressed intimal hyperplasia in a rat carotid injury model."
01/01/2003 - "A single intravenous administration of monoclonal antibody against PDGF-beta receptor failed to reduce the amount of neointimal hyperplasia after stent implantation."
09/12/2000 - "A single-bolus luminal delivery of antisense PDGFR-beta to injured rat carotids reduced intimal hyperplasia, improved the reendothelialization process, and led to the recovery of endothelium-dependent regulation of vascular tone."
06/01/2014 - "Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma."
02/07/1996 - "The results obtained in this study demonstrate that malignant mesothelioma cell lines are not only capable of PDGF beta-receptor transcription but of alpha-receptor transcription as well, as evidenced from run off analysis and RT-PCR using alpha-receptor specific primers. "
02/07/1996 - "Such an analysis is of importance in view of the suggested PDGF autocrine activity involving the PDGF beta-receptor mesothelioma cells. "
02/01/1996 - "PDGF beta-receptors and occasionally PDGF alpha-receptors were detected in frozen tissue sections of malignant mesotheliomas, whereas mesothelioma cells in effusions showed faint expression of only the PDGF beta-receptor. "
09/01/1995 - "We found a high incidence of immunocytochemical expression for c-myc, WT-1, p53 and PDGF-beta receptor in the cells suggesting strongly that these markers are playing certain roles in the development of human malignant mesothelioma. "
11/01/2009 - "In addition to PDGFRB, mTOR pathway can be activated in chordomas and the combination of IM plus rapalogs may be effective in IM-resistant chordomas."
07/25/2011 - "Histopathological features of 42 chordoma specimens, 21 primary and 21 advanced, were assessed by immunohistochemistry and fluorescent in situ hybridization (FISH) using PDGFRB, CSF1R, and EGFR probes. "
12/01/2006 - "This article describes the results of comprehensive molecular/biochemical analyses of the three receptors targeted by the drug (PDGFRB, PDGFRA, and KIT) in a series of 31 chordoma patients. "
07/01/2007 - "We analyzed 14 chordoma samples for the expression of the Imatinib mesylate targets by means of RT-PCR and immunohistochemistry and found that PDGFR alpha and PDGFR beta are in some cases expressed in neoplastic cells, while the stromal counterpart of the same tumor shows the above receptors. "
03/20/2012 - "In a collaborative Italian-Swiss, prospective, phase II clinical study conducted from November 2004 through April 2006, 56 patients with advanced PDGFB and/or PDGFRB chordoma received 800 mg/d of imatinib until progression. "
|5.||Wounds and Injuries (Trauma)
04/01/1999 - "Immunostaining revealed that both injuries induced cell proliferation and the upregulation of beta PDGFR but not alpha PDGFR. "
02/01/1997 - "Expression of PDGF beta-receptor appears later at the wound site, indicating that the PDGF B isomer may regulate later wound healing events."
05/01/1993 - "An increased expression of PDGF beta receptor protein was prominent in vessels in the proliferating tissue zone in wounds as early as 1 d after surgery and was apparent < or = 4 wk after surgery. "
11/01/2001 - "[A preliminary study on the changes of expression of PDGF-beta, PDGFR-beta, TGF-beta 1, TGFR, bFGF and its relationship with the wound age in wound healing]."
05/01/1993 - "Expression of PDGF beta receptor protein and PDGF-AB/BB were analyzed in wound margin biopsies using the PDGFR-B2 and PDGF 007 antibodies. "
|2.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|3.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||platelet-derived growth factor BB (becaplermin)
|9.||Death Domain Receptors
|10.||Collagen Type I (Type I Collagen)
|2.||Heterologous Transplantation (Xenotransplantation)